Application of the seattle heart failure model in patients on cardiac resynchronization therapy

PACE - Pacing and Clinical Electrophysiology

Volumn 35, Issue 1, 2012, Pages 88-94

  Perrotta, Laura ^a   Ricciardi, Giuseppe ^a   Pieragnoli, Paolo ^a   Chiostri, Marco ^a   Pontecorboli, Giulia ^a   De Santo, Tiziana ^b   Bellocci, Fulvio ^c   Vitulano, Nicola ^c   Emdin, Michele ^d   Mascioli, Giosuè ^e   Ricceri, Ilaria ^a   Porciani, Maria Cristina ^a   Michelucci, Antonio ^a   Padeletti, Luigi ^a,e  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Medtronic Italia   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Fondazione Monasterio   (Italy)

^e Humanitas Gavazzeni Hospital   (Italy)

Author keywords

cardiac resynchronization therapy; heart failure; Seattle Heart Failure Score

Indexed keywords

ALDOSTERONE ANTAGONIST; GLUCOSE;

ADULT; AGE; AGED; ARTICLE; CARDIAC PATIENT; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ASSESSMENT TOOL; DEFIBRILLATOR; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; QRS COMPLEX; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEATTLE HEART FAILURE MODEL SCORE; SENSITIVITY AND SPECIFICITY;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; HEART FAILURE; HUMANS; ITALY; MALE; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84855905514     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2011.03258.x     Document Type: Article

References (31)

1. Lloyd-Jones D, Adams R, Carnethon M,. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e101-e104.
2. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, et al,. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25: 1614-1619. (Pubitemid 39209281)
3. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ,. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292: 344-350. (Pubitemid 38944258)
4. Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA,. Long-term survival after heart failure: A contemporary population-based perspective. Arch Intern Med 2007; 167: 490-496. (Pubitemid 46425662)
5. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ,. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-322. (Pubitemid 32895839)
6. Neumann PJ, Rosen AB, Weinstein MC,. Medicare and cost-effectiveness analysis. N Engl J Med 2005; 353: 1516-1522. (Pubitemid 41400929)
7. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ,. Effects of cardiac resynchronization therapy on overall mortality and mode of death: A meta-analysis of randomized controlled trials. Eur Heart J 2006; 27: 2682-2688. (Pubitemid 44729869)
8. McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, et al,. Systematic review: Cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 381-390.
9. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al,. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systematic review. JAMA 2007; 297: 2502-2514. (Pubitemid 46953404)
10. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM,. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplante evaluation. Circulation 1997; 95: 2660-2667. (Pubitemid 27255495)
11. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV,. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003; 290: 2581-2587. (Pubitemid 37443288)
12. Koelling TM, Joseph S, Aaronson KD,. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004; 23: 1414-1422. (Pubitemid 40018165)
13. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S,. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004; 116: 300-304. (Pubitemid 38230288)
14. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ,. ADHERE Scientific Advisory Committee, study group, and investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. JAMA 2005; 293: 572-580. (Pubitemid 40171239)
15. O'Connor CM, Hasselblad V, Mehta RH, Tasissa G, Califf RM, Fiuzat M, Rogers JG, et al,. Triage after hospitalization with advanced heart failure. The ESCAPE (evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness) risk model and discharge score. JACC 2010; 55: 872-878.
16. Butler J, Kalogeropoulos A, Georgiopoulou V, Belue R, Rodondi N, Garcia M, Bauer DC, et al,. Health ABC study. Incident heart failure prediction in the elderly: The health ABC heart failure score. Circ Heart Fail 2008; 1: 125-133.
17. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, et al,. The Seattle heart failure model. Prediction of survival in heart failure. Circulation 2006; 113: 1424-1433. (Pubitemid 43739439)
18. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, Carson PE, et al,. Prediction of mode of death in heart failure. The Seattle Heart Failure model. Circulation 2007; 116: 392-398. (Pubitemid 47196544)
19. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, et al,. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51: e1-e62.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
21. Goldberg LR, Jessup M,. A time to born and a time to die. Circulation 2007; 116: 360-362.
22. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, et al,. For the prospective randomized amlodipine survival evaluation study group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114. (Pubitemid 26330964)
23. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, et al., Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Effect of cardiac resynchronization therapy with or without an implantable defibrillator in advanced heart failure. N Engl J Med 2004; 350: 2140-2150.
24. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, et al,.; CARE-HF study Steering Committee and Investigators.on behalf of The CARE-HF study Steering Committee and Investigators. The CARE-HF study (Cardiac Resynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail 2001; 3: 481-489. (Pubitemid 32776875)
25. May HT, Horne BD, Levy WC, Kfoury AG, Rasmusson KD, Linker DT, Mozaffarian D, et al,. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007; 100: 697-700.
26. Allen LA, Yager JE, Funk MJ, Levy WC, Tulsky JA, Bowers MT, Dodson GC, et al,. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA 2008; 299: 2533-2542. (Pubitemid 351787209)
27. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, Agha SA, Rashad MA, Laskar SR, Smith AL, et al,. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J 2009; 157: 299-305.
28. Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hellmich M, Erdmann E, Schneider CA,. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 2008; 10: 315-320.
29. Levy WC, Mozaffarian D, Linker TD, Farrar DJ, Miller LW,. On behalf of the REMATCH investigators. Can the Seattle Heart Failure Model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009; 28: 231-236.
30. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, Maggioni AP, et al,. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120: 835-842.
31. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, Smith AL, Agha SA, Waheed S, Laskar S, et al,. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009; 53: 334-342.